>
pdufa.bio

ARD-101

Updated ยทnext FDA decision on the calendar

ARD-101 is a Aardvark Therapeutics, Inc. program. Its next catalyst is a Readout in Q3 2026. Every date links its source.

AARD catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Aardvark Therapeutics, Inc. (AARD). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q3 2026AARD

Questions

When is ARD-101's next FDA decision or readout?

The next tracked catalyst for ARD-101 is a Readout in Q3 2026.

What happened at ARD-101's most recent FDA decision?

No FDA decision for ARD-101 is in our archive yet.

Who makes ARD-101?

Aardvark Therapeutics, Inc. (AARD).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.